151. Quitlines and nicotine replacement for smoking cessation: do we need to change policy?
- Author
-
Pierce, John P, Cummins, Sharon E, White, Martha M, Humphrey, Aimee, and Messer, Karen
- Subjects
Humans ,Nicotinic Agonists ,Treatment Outcome ,Smoking ,Smoking Cessation ,Counseling ,Health Policy ,Social Support ,Hotlines ,Telephone ,Randomized Controlled Trials as Topic ,Tobacco Use Cessation Devices ,Cancer ,Drug Abuse (NIDA only) ,Tobacco Smoke and Health ,Prevention ,Substance Misuse ,Clinical Research ,Clinical Trials and Supportive Activities ,Tobacco ,3.1 Primary prevention interventions to modify behaviours or promote wellbeing ,Prevention of disease and conditions ,and promotion of well-being ,Stroke ,Respiratory ,Good Health and Well Being ,tobacco control ,pharmaceutical aids ,population research ,Public Health and Health Services ,Public Health - Abstract
In the past 20 years, public health initiatives on smoking cessation have increased substantially. Randomized trials indicate that pharmaceutical cessation aids can increase success by 50% among heavier smokers who seek help, and use of these aids has increased markedly. Quitlines provide a portal through which smokers can seek assistance to quit and are promoted by tobacco control programs. Randomized trials have demonstrated that telephone coaching following a quitline call can also increase quitting, and a combination of quitlines, pharmaceutical aids and physician monitoring can help heavier smokers to quit. While quit attempts have increased, widespread dissemination of these aids has not improved population success rates. Pharmaceutical marketing strategies may have reduced expectations of the difficulty of quitting, reducing success per attempt. Some policies actively discourage unassisted smoking cessation despite the documented high success rates of this approach. There is an urgent need to revisit public policy on smoking cessation.
- Published
- 2012